阿托伐他汀对扩张型心肌病患者心功能及C-反应蛋白的影响  

THE EFFECT OF ATROPHATADINE ON HEART FUNCTION AND SERUM CRP IN PATIENTS WITH DILATED CARDIOMYOPATHY

作　　者：李泽林[1] 孙华保[1] 宁丹霞[1] 李庆军[1] 梁国钦[1] 王广兴[1] 

机构地区：[1]湛江中心人民医院,广东湛江524037

出　　处：《现代医院》2008年第7期34-36,共3页Modern Hospitals

摘　　要：目的观察阿托伐他汀治疗扩张型心肌病患者对心功能及C-反应蛋白的影响。方法将扩张型心肌病患者82例随机分为阿托伐他汀(20mg/d)组(n=41)与对照组(n=41),两组均按慢性心力衰常规治疗,治疗组另外服用阿托伐他汀,两组治疗前后检查NYHA分级、6分钟步行距离、TC、hsCRP、LVEDD、LVESD、LVEF。结果6个月后,阿托伐他汀组与对照组治疗前后差值相比,TC(p<0.01)、hsCRP(p<0.01)、LVEDD(p<0.05)、LVESD(p<0.01)均有不同程度降低,NYHA分级(p<0.05)、6分钟步行距离(p<0.01)、LVEF(p<0.01)则有明显提高。结论扩张型心肌病患者在常规扩心衰治疗基础上加用阿托伐他汀20mg/d治疗6个月可显著改善左室功能,降低C-反应蛋白水平。Objective To observe the changement of serum creactive protein（ CRP） and cardic function with atrophatadine therapy in dilated cardiomyopathy patients. Methods 82 patients with dilated cardiomyopathy were randomly divided into treated group and contol group, which were given usual treatment. Meanwhile, atrophata-dine 20 mg/d was added to the treated group. Two groups need to detected the patients, NYHA stage, 6 minutes walk test,TC,CRP,LVEDD,LVESD and LEVF before and after treatment. Results After 6 months,compared to the control group, the TC（p 〈0. 01 ） ,CRP（p 〈0. 01 ） ,LVEDD（p 〈0. 05 ）, LVESD（p 〈0. 01 ） of the treated group decreased in varying degredd,but the patients, NYHA stage（p 〈0. 05）, 6 minutes walk test（p 〈0.01 ） and LEVF（p 〈0. 01 ） increased obviously. Conclusion Atrophatadine was effective in treat dilater cardiomyopathypatients and can significantly improve cardiac functions as well as reduce the levels of Creactive protein.

关 键 词：扩张型心肌病 慢性心衰 阿托伐他汀 C-反应蛋白 

分 类 号：R542.2[医药卫生—心血管疾病] R541.4[医药卫生—内科学]